Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives

Bibliography

• McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013;188(6):647-56
   PubMed Web of Science ®Google Scholar
• Siekmeier R, Hofmann T, Scheuch G. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. Adv Exp Med Biol 2015;839:13-24
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013;55(1):27-34
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12(4):205-9
   Google Scholar
• Rubin BK, Williams RW. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. Respiration 2014;88:177-84
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Hadid W, Ericsoussi B, et al. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis 2013;17(11):e1000-e04
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-65
   PubMed Web of Science ®Google Scholar
• Sidhu MK, Mandal P, Hill AT. Developing drug therapies in bronchiectasis. Exp Opin Drug Deliv 2014;24(2):169-81
   Web of Science ®Google Scholar
• Xiong MH, Bao Y, Yang XZ, et al. Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev 2014;78:63-76
   PubMed Web of Science ®Google Scholar
• Weers J. Inhaled antimicrobial therapy - Barriers to effective treatment. Adv Drug Deliv Rev 2015;85:24-43
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-cystic fibrosis bronchiectasis. Thorax 2010;65(Suppl 1):i1-i58
   PubMed Web of Science ®Google Scholar
• McCullough AR, Tunney MM, Quittner AL, et al. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med 2014;14:107
   PubMed Web of Science ®Google Scholar
• Respiratory Expert Group. Therapeutic Guidelines: Respiratory. 5th edition. Therapeutic Guidelines Limited, Melbourne; 2015
   Google Scholar
• Antibiotic Expert Group. Therapeutic guidelines: Antibiotics. 5th edition. Therapeutic Guidelines Limited, Melbourne; 2014
   Google Scholar
• Cipolla D, Chan HK. Inhaled antibiotics to treat lung infection. Pharm Pat Anal 2013;2(5):647-63
   PubMedGoogle Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial. Thorax 2013;68(9):812-17
   PubMed Web of Science ®Google Scholar
• Weers J, Tarara T. The PulmoSphere platform for pulmonary drug delivery. Ther Deliv 2014;5(3):277-95
   PubMedGoogle Scholar
• Weers JG, Bell J, Chan HK, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 2):S5-23
   PubMedGoogle Scholar
• Weers J, Ung K, Le J, et al. Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subject’s inhalation maneuver. J Aerosol Med Pulm Drug Deliv 2013;26(1):56-68
   PubMed Web of Science ®Google Scholar
• Stass H, Nagelschmitz J, Willmann S, et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig 2013;33(6):419-27
   PubMed Web of Science ®Google Scholar
• Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther 2013;35(10):1571-81
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5):1107-15
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2):481-5
   PubMed Web of Science ®Google Scholar
• Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189(8):975-82
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JRW, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-9
   PubMed Web of Science ®Google Scholar
• Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93(7):476-80
   PubMed Web of Science ®Google Scholar
• Tabernero E, Gil P, Alkiza R, et al. Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection. Chest 2014;145(Suppl 3):431A
   Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2(9):738-49
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10
   PubMed Web of Science ®Google Scholar
• Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: A systematic review. Eur Respir J 2014;44(2):382-93
   PubMed Web of Science ®Google Scholar
• Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2014;11:CD004197
   PubMedGoogle Scholar
• White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012;106(3):356-60
   PubMed Web of Science ®Google Scholar
• Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183(11):1510-16
   PubMed Web of Science ®Google Scholar
• Schuster A, Haliburn C, Döring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68(4):344-50
   PubMed Web of Science ®Google Scholar
• Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012;185(2):171-8
   PubMed Web of Science ®Google Scholar
• McCaughey G, McKevitt M, Elborn JS, et al. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 2012;11(3):163-72
   PubMed Web of Science ®Google Scholar
• MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009;64(4):829-36
   PubMed Web of Science ®Google Scholar
• Clinical trial registry and database. Available from: https://clinicaltrials.gov [Last accessed 27 July 2015]
   Google Scholar
• Fowler SJ, French J, Screaton NJ, et al. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur Respir J 2006;28(6):1204-10
   PubMed Web of Science ®Google Scholar
• Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23(3):590-615
   PubMed Web of Science ®Google Scholar
• Wu Q, Shen W, Cheng H, et al. Long-term macrolides for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Respirology 2014;19(3):321-9
   PubMed Web of Science ®Google Scholar
• Togami K, Chono S, Morimoto K. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. J Aerosol Med Pulm Drug Deliv 2012;25(2):110-15
   PubMed Web of Science ®Google Scholar
• Moghaddam PH, Ramezani V, Esfandi E, et al. Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol 2013;239:478-83
   Web of Science ®Google Scholar
• Togami K, Chono S, Seki T, et al. Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. Drug Dev Ind Pharm 2010;36(7):861-6
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Lu D, Ashley ED, et al. Inhaled azithromycin therapy. J Aerosol Med 2006;19(1):54-60
   PubMedGoogle Scholar
• Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014;75:81-91
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997;154(2):123-40
   Web of Science ®Google Scholar
• Willis L, Hayes DJr, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012;190(3):251-62
   PubMed Web of Science ®Google Scholar
• Cheow WS, Hadinoto K. Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly (lactic-co-glycolic acid) nanoparticles: Modifications of standard nanoparticle preparation methods. Colloids Surf A 2010;370(1):79-86
   Web of Science ®Google Scholar
• Misra A, Jinturkar K, Patel D, et al. Recent advances in liposomal dry powder formulations: preparation and evaluation. Exp Opin Drug Deliv 2009;6(1):71-89
   PubMed Web of Science ®Google Scholar
• Gaspar MM, Bakowsky U, Ehrhardt C. Inhaled liposomes--current strategies and future challenges. J Biomed Nanotechnol 2008;4(3):245-57
   Web of Science ®Google Scholar
• Mugabe C, Azghani AO, Omri A. Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int J Pharm 2006;307(2):244-50
   PubMed Web of Science ®Google Scholar
• Alipour M, Halwani M, Omri A, et al. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm 2008;355(1-2):293-8
   PubMed Web of Science ®Google Scholar
• Wallace SJ, Nation RL, Li J, et al. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J Pharm Sci 2013;102(5):1578-87
   PubMed Web of Science ®Google Scholar
• Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Ther Deliv 2013;4(8):1047-72
   PubMedGoogle Scholar
• Ungaro F, d’Angelo I, Miro A, et al. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 2012;64(9):1217-35
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189(5):576-85
   PubMed Web of Science ®Google Scholar
• Poppelwell L, Chalmers JD. Defining severity in non-cystic fibrosis bronchiectasis. Exp Rev Respir Med 2014;8(2):249-62
   PubMed Web of Science ®Google Scholar
• Metersky ML, O’Donnell AE. Nebulized colistin for non-cystic fibrosis bronchiectasis: deja vu all over again? Am J Respir Crit Care Med 2014;189(10):1151-2
   PubMed Web of Science ®Google Scholar
• De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax 2013;68(7):695-6
   PubMed Web of Science ®Google Scholar
• Fried LP, Ferrucci L, Darer J, et al. Untangling the Concepts of Disability, Frailty, and Comorbidity: Implications for Improved Targeting and Care. J Gerontol A Biol Sci Med Sci 2004;59(3):M255-M63
   PubMed Web of Science ®Google Scholar
• Greally P, Whitaker P, Peckham D. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Med Res Opin 2012;28(6):1059-67
   PubMed Web of Science ®Google Scholar
• Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 2014;11(3):425-34
   PubMedGoogle Scholar
• Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014;13(6):692-8
   PubMed Web of Science ®Google Scholar
• Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care 2010;55(7):911-21
   PubMed Web of Science ®Google Scholar
• Alipour M, Suntres ZE. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa. Ther Deliv 2014;5(4):409-27
   PubMedGoogle Scholar
• Hoffman LR, D’Argenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005;436(7054):1171-5
   PubMed Web of Science ®Google Scholar
• Quittner AL, O’Donnell AE, Salathe MA, et al. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax 2015;70(1):12-20
   PubMed Web of Science ®Google Scholar
• Rogers GB, Van Der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68(8):731-7
   PubMed Web of Science ®Google Scholar
• Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014;11(4):496-503
   PubMedGoogle Scholar
• Gonem S, Scadding A, Soares M, et al. Lung clearance index in adults with non-cystic fibrosis bronchiectasis. Respir Res 2014;15:59
   PubMed Web of Science ®Google Scholar
• Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010;193(6):356-65
   PubMed Web of Science ®Google Scholar
• Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009;136(6):1521-8
   PubMed Web of Science ®Google Scholar
• Martínez-García M-A, de la Rosa Carrillo D, Soler-Cataluña J-J, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(8):823-31
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141(2):461-8
   PubMed Web of Science ®Google Scholar
• Mukker JK, Singh RSP, Derendorf H. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy. Adv Drug Deliv Rev 2015;85:57-64
   PubMed Web of Science ®Google Scholar
• Velkov T, Abdul Rahim N, Zhou Q, et al. Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. Adv Drug Deliv Rev 2015;85:65-82
   PubMed Web of Science ®Google Scholar
• Hittinger M, Juntke J, Kletting S, et al. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. Adv Drug Deliv Rev 2016;85:44-56
   Web of Science ®Google Scholar
• Tre-Hardy M, Nagant C, El Manssouri N, et al. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 2010;54(10):4409-15
   PubMed Web of Science ®Google Scholar
• Elkhatib W, Noreddin A. Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. Microb Drug Resist 2014;20(6):575-82
   PubMed Web of Science ®Google Scholar
• Lee SH, Teo J, Heng D, et al. Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. Eur J Pharm Biopharm 2013;83(2):275-84
   PubMed Web of Science ®Google Scholar
• El-Din MA, Palmer LB, el-Tayeb MN, et al. Nebulizer therapy with antibiotics in chronic suppurative lung disease. J Aerosol Med 1994;7(4):345-50
   PubMedGoogle Scholar
• Aquino RP, Prota L, Auriemma G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm 2012;426(1-2):100-7
   PubMed Web of Science ®Google Scholar
• Ungaro F, d’Angelo I, Coletta C, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012;157(1):149-59
   PubMed Web of Science ®Google Scholar
• Beaulac C, Clément-Major S, Hawari J, et al. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother 1996;40(3):665-9
   PubMed Web of Science ®Google Scholar
• Beaulac C, Sachetelli S, Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Target 1999;7(1):33-41
   PubMed Web of Science ®Google Scholar
• Alhajlan M, Alhariri M, Omri A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother 2013;57(6):2694-704
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X, Lin X, et al. High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm 2010;395(1-2):205-14
   PubMed Web of Science ®Google Scholar
• Adi H, Young PM, Chan H-K, et al. Co-spray-dried mannitol–ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci 2010;40(3):239-47
   PubMed Web of Science ®Google Scholar
• Arnold MM, Gorman EM, Schieber LJ, et al. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release 2007;121(1–2):100-9
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Cipolla D, et al. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res 2012;29(12):3335-46
   PubMed Web of Science ®Google Scholar
• Pastor M, Moreno-Sastre M, Esquisabel A, et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 2014;477:485-94
   PubMed Web of Science ®Google Scholar
• Adi H, Young PM, Chan HK, et al. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 2008;97(8):3356-66
   PubMed Web of Science ®Google Scholar
• Adi H, Young PM, Chan HK, et al. Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm 2010;36(1):119-26
   PubMed Web of Science ®Google Scholar
• Lee SH, Teo J, Heng D, et al. A novel inhaled multi-pronged attack against respiratory Bacteria. Eur J Pharm Sci 2015;70:37-44
   PubMed Web of Science ®Google Scholar
• Park CW, Li X, Vogt FG, et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm 2013;455(1-2):374-92
   PubMed Web of Science ®Google Scholar
• Pilcer G, Rosiere R, Traina K, et al. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci 2013;102(6):1836-46
   PubMed Web of Science ®Google Scholar